Neoadjuvant chemotherapy in ovarian cancer: Are there racial disparities in use and survival?
Saber A AminLindsay J CollinSoko SetoguchiJaya M SatagopanAlexandre Buckley de MeritensElisa V BanderaPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)
Differences in treatment sequence did not explain racial disparities in ovarian cancer mortality. Further evaluation of racial and ethnic differences in treatment and survival in a cohort of patients with detailed treatment information is warranted.